Sangamo Therapeutics (SGMO) EBIAT (2016 - 2025)
Sangamo Therapeutics (SGMO) has 16 years of EBIAT data on record, last reported at -$34.9 million in Q3 2025.
- For Q3 2025, EBIAT fell 427.31% year-over-year to -$34.9 million; the TTM value through Sep 2025 reached -$108.9 million, up 19.23%, while the annual FY2024 figure was -$97.9 million, 62.01% up from the prior year.
- EBIAT reached -$34.9 million in Q3 2025 per SGMO's latest filing, down from -$20.0 million in the prior quarter.
- Across five years, EBIAT topped out at $21.1 million in Q1 2023 and bottomed at -$114.5 million in Q2 2023.
- Average EBIAT over 5 years is -$42.7 million, with a median of -$44.0 million recorded in 2022.
- Peak YoY movement for EBIAT: crashed 3062.33% in 2021, then soared 148.05% in 2023.
- A 5-year view of EBIAT shows it stood at -$37.5 million in 2021, then crashed by 38.61% to -$52.0 million in 2022, then fell by 16.01% to -$60.3 million in 2023, then soared by 61.2% to -$23.4 million in 2024, then plummeted by 49.3% to -$34.9 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$34.9 million in Q3 2025, -$20.0 million in Q2 2025, and -$30.6 million in Q1 2025.